← back to rankingA · Agilent Technologies, Inc.
Medical - Diagnostics & Research · mkt cap $38.2B · calls: Q2 FY2026 vs Q1 FY2026
39.0 conviction · conf-adj 39
conf – 🚀 reported
enthusiasm:24.0 · trend:8 · quantifies:0 · impact:0 · under_radar:0 · credibility:0 · business_impact:4 · disruption:0 · commitment:0 · confirmation:3
Enthusiasm latest 8 / prev 5 (rising)
Agilent’s AI thesis shifted from targeted internal AI initiatives in Q1 to a broader Q2 narrative: AI as an enterprise focus, an internal supply-chain productivity tool, and a demand driver for pharma wet labs and downstream QA/QC. Management did not quantify AI’s direct revenue, margin, cost, or productivity impact with a specific figure. Credibility is moderate: the thesis is strategically coherent and tied to Agilent’s actual end markets, but the disclosed evidence remains qualitative.
PAST (realized)
- We built our AI-enabled supply chain control tower to create greater prediction and adaptive calibration of our supply and demand plans, leading to inherent resiliency, faster issue response times and much higher scheduled attainment.
- After implementing this new capability, we have seen continued meaningful improvement in scheduled plan attainment, order conversion ratios and overall cycle times.
CURRENT (now)
- Last but not least, AI is a key FY '26 enterprise focus area for us.
- Pharma customers are leaning into AI to accelerate drug development and reduce the odds of expensive late-stage failures.
- Beyond being accretive to our top line in the medium term, we are also deploying AI within our own business.
- The offering includes embedding our expert on-site support technicians and customer sites and leveraging digital capabilities through CrossLab Connect that provide monitoring, alerting and performance analytics.
FORWARD (guidance)
- Leveraging the country's deep base of technical talent and a vibrant innovation ecosystem we intend to strengthen our R&D capabilities across multiple emerging areas, including digital, AI and automation to better support our customers.
- AI has the potential to be a tremendous growth driver for the life sciences industry.
- There is a growing need for a large-scale multimodal data sets to train AI models, which will require significant investments in the wet lab.
- By moving the needle on drug development ROI, AI holds the promise of putting our largest customer constituency on a better footing and a higher number of approvals coming through the drug pipeline should be a strong tailwind for us, given our leading position in downstream manufacturing QA/QC workflows.
- In light of the regulatory and patient safety aspects of commercial scale drug manufacturing, we believe this part of the value chain will meaningfully benefit from AI use upstream.
- These work streams include increasing returns and innovation investments by improving speed to market, advancing digital and e-commerce capability to enhance commercial productivity, and deploying targeted artificial intelligence initiatives with clear ROI to enhance customer insights, automate routine work and compress manufacturing cycle times.
- Also on the chemical side, you have downstream processes that are needed for AI that supports that in terms of it, and that really bolsters a lot of demand.
TRACK RECORD — PROMISE vs DELIVERY
—/100 (no quantified promises) no-quantified-promises 6 calls reviewed
Across these six calls, Agilent showed real AI/intelligent-automation substance (ABB lab robotics, InfinityLab Assist on-board intelligence, an AI-enabled supply-chain control tower, and internal wins like AI generating 80% of engineering drawings and cutting custom GC design cycle times 75%), but every instance was disclosed as an already-achieved current fact or framed as qualitative forward intent ('deploying targeted AI initiatives with clear ROI', 'sharing more on our AI efforts soon'). Management never set a forward-looking AI target combining both a number and a timeframe/milestone, so there is no quantified AI promise to score for delivery.
PRICED-IN (REFINED)
HIGH (already in)Est. revisions rising · Fwd P/E 24.2 · EV/Sales 5.5x
AI claim maps to Life Sciences and Applied Markets, Agilent CrossLab, Diagnostics and Genomics
Analyst ratings have migrated upward, with holds falling from 8 in January 2026 to 2 in June 2026 and buy/strong-buy concentration increasing, while forward revenue and EPS estimates show steady mid-to-high single-digit growth. The valuation is rich for a mature diagnostics and research tools company at 24.2x forward EPS and 5.5x EV/sales, with TTM P/E around 27x. AI benefits would most plausibly flow through Life Sciences and Applied Markets, Agilent CrossLab, and Diagnostics and Genomics, but rising estimates plus a premium multiple mean more of that upside is already priced in.
COVERAGE — ENTHUSIASM TRAJECTORY + CATALYSTS
6Q1 FY20253Q2 FY20253Q3 FY20258Q4 FY20255Q1 FY20267Q2 FY2026
AI enthusiasm across 6 calls — trend ↗ rising
AI moved from lab automation mentions to specific internal productivity, CRM, service analytics, and intelligent instrument features.
RECENT AI CATALYSTS & NEWS
BUSINESS IMPACT - QUALITATIVE MATERIALITY
6/10 qualitative impact moderate medium-term · mixed evidence
Where AI matters: lab automation, instrument intelligence, supply chain, CrossLab analytics
Agilent has credible internal and product-adjacent AI deployment in supply-chain planning, engineering workflows, service analytics, and intelligent lab/instrument automation, but management has not tied it to direct revenue, EPS, or margin targets. The pharma wet-lab demand thesis is strategically plausible, but partly indirect and should not be scored like a clear monetized AI product cycle.
Caveats: No quantified AI revenue, EPS, margin, or cost target disclosed; Some claimed benefits remain qualitative or internal productivity rather than monetized customer demand; AI-driven lab efficiency could reduce some incremental instrument or service needs if utilization improves; Customer pharma funding and China demand remain bigger swing factors than AI adoption alone
AI DISRUPTION / CANNIBALIZATION RISK tailwind · 2/10
AI does not plausibly automate away Agilent's core regulated instruments, consumables, lab services, and QA/QC workflows; if anything, better drug discovery and larger multimodal datasets can increase wet-lab and downstream testing demand. Some software/automation could pressure service intensity or instrument utilization, but the hardware, compliance, and installed-base economics remain durable.
OPTIONS / MARKET STRUCTURE
option liquidity: good
proxy inputs — dollar-ADV $306M · beta 1.219 · px $135.04
source: proxy (no options chain on FMP)
FMP /stable/ exposes no options-chain endpoint on this key, so ATM IV, bid-ask spread and open interest are unavailable. Liquidity below is a PROXY from dollar-ADV, beta and price level (a stand-in for option depth), not measured option-market data.
CONFIRMATION — INSIDERS · 13F · LANGUAGE
Mixed — insiders selling, institutions adding, management language 4/10 measured.
INSIDERS selling 1 open-market sell(s) vs 0 buy(s) — net distribution
INSTITUTIONS (13F) adding as of 2026-03-31: 105 new / 185 closed positions; 504 increased / 374 reduced; institutional ownership -0.89pp; -81 net 13F holders
MGMT LANGUAGE 4/10 measured AI is barely discussed; automation is tied to products and R&D, but language is mostly potential-oriented and customer-facing.
commit “including digital, AI and automation to better support our customers.”
hedge “we see excellent potential to build on our in-house capabilities with unique automation development expertise in China.”
commit “where our customers increasingly prioritize efficiency automation and total cost of ownership.”
VERBATIM AI QUOTES
“Leveraging the country's deep base of technical talent and a vibrant innovation ecosystem we intend to strengthen our R&D capabilities across multiple emerging areas, including digital, AI and automation to better support our customers.”
— Padraig McDonnell, Q2 FY2026
“We built our AI-enabled supply chain control tower to create greater prediction and adaptive calibration of our supply and demand plans, leading to inherent resiliency, faster issue response times and much higher scheduled attainment.”
— Padraig McDonnell, Q2 FY2026
“After implementing this new capability, we have seen continued meaningful improvement in scheduled plan attainment, order conversion ratios and overall cycle times.”
— Padraig McDonnell, Q2 FY2026
“Last but not least, AI is a key FY '26 enterprise focus area for us.”
— Padraig McDonnell, Q2 FY2026
“AI has the potential to be a tremendous growth driver for the life sciences industry.”
— Padraig McDonnell, Q2 FY2026
“Pharma customers are leaning into AI to accelerate drug development and reduce the odds of expensive late-stage failures.”
— Padraig McDonnell, Q2 FY2026
“There is a growing need for a large-scale multimodal data sets to train AI models, which will require significant investments in the wet lab.”
— Padraig McDonnell, Q2 FY2026
“By moving the needle on drug development ROI, AI holds the promise of putting our largest customer constituency on a better footing and a higher number of approvals coming through the drug pipeline should be a strong tailwind for us, given our leading position in downstream manufacturing QA/QC workflows.”
— Padraig McDonnell, Q2 FY2026
“In light of the regulatory and patient safety aspects of commercial scale drug manufacturing, we believe this part of the value chain will meaningfully benefit from AI use upstream.”
— Padraig McDonnell, Q2 FY2026
“Beyond being accretive to our top line in the medium term, we are also deploying AI within our own business.”
— Padraig McDonnell, Q2 FY2026
“we're fully aligned with the China 15, 5-year plan around AI, health care green and sustainable developments and, of course, new regulations around PFAS.”
— Padraig McDonnell, Q2 FY2026
“The offering includes embedding our expert on-site support technicians and customer sites and leveraging digital capabilities through CrossLab Connect that provide monitoring, alerting and performance analytics.”
— Padraig McDonnell, Q1 FY2026
“These work streams include increasing returns and innovation investments by improving speed to market, advancing digital and e-commerce capability to enhance commercial productivity, and deploying targeted artificial intelligence initiatives with clear ROI to enhance customer insights, automate routine work and compress manufacturing cycle times.”
— Padraig McDonnell, Q1 FY2026
“Also on the chemical side, you have downstream processes that are needed for AI that supports that in terms of it, and that really bolsters a lot of demand.”
— Padraig McDonnell, Q1 FY2026
ANALYST QUESTIONS ON AI
Q (Q2 FY2026, Luke Sergott): Can you -- you guys had a really strong quarter like you guys were talking about on gross margin, getting the volume leverage, but then you're talking about some increased investment there, like pull forward on the ICPMS launch. Like can you just talk about where -- how much is being pulled forward on these investments and how that kind of shakes out?
A: And once again, that incorporates several things. It's the structural improvements from Ignite, the volume leverage that we expect to get offset by inflation, and that's inflation kind of in the broad sense as well as some of the logistical Middle East costs in the AI and chip costs that we're seeing as well as then those growth investments.
Q (Q2 FY2026, Michael Ryskin): You talked about slower funding delays in funding in China. Anything more specific than that? Or is it really that focused?
A: we have the largest installed base, the pace of innovation, everybody can read the details on that, and we're fully aligned with the China 15, 5-year plan around AI, health care green and sustainable developments and, of course, new regulations around PFAS.
Q (Q1 FY2026, Daniel Leonard): Padraig, you talked about atomic spectroscopy upside in the quarter due to the memory shortage. It's not something you talk about a lot. So how are you framing that opportunity?
A: Also on the chemical side, you have downstream processes that are needed for AI that supports that in terms of it, and that really bolsters a lot of demand.